Evaluation of potential immune-related adverse events in mouse lung tissues after anti-PD1 or anti-PD1 nanocapsule treatment
RNA-seq (gene expression) · mouse · 9 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 9 samples: 3 × Anti-PD1 vs 3 × Nanocapsule_Anti-PD1 vs 3 × ControlGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Universal diseased-site targeting via glycolysis-driven lactic acid gradientScience advances · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE321667_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1429265 and SRA study SRP679763. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 9 samples.
How we read this: 3 replicated groups read from 9 sample titles; they account for 9 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9549382 Anti-PD1_1 Anti-PD1
- GSM9549383 Anti-PD1_2 Anti-PD1
- GSM9549384 Anti-PD1_3 Anti-PD1
- GSM9549385 Nanocapsule_Anti-PD1_1 Nanocapsule_Anti-PD1
- GSM9549386 Nanocapsule_Anti-PD1_2 Nanocapsule_Anti-PD1
- GSM9549387 Nanocapsule_Anti-PD1_3 Nanocapsule_Anti-PD1
- GSM9549388 Control_1 Control
- GSM9549389 Control_2 Control
- GSM9549390 Control_3 Control
- GSE311831 Pertussis toxin-induced lymphocytosis enhances anti-tumor immune environments and improves the anti-PD1 treatment response in a squamous cell carcinoma model. 24 samples shares anti-pd1, treatment
- GSE248513 Combining anti-PD1 and vorinostat improves anti-tumor treatment in IDH-mutant brain tumors 15 samples shares anti-pd1, treatment
- GSE265943 Gene expression analysis at single cell level from the CNS of mice that harbored Melanoma and recieved Anti-PD1 antibody or Isotype control antibody treatment 2 samples shares anti-pd1, treatment
- GSE304231 CITE-seq analysis of murine subcutaneos PDAC tumor models under pan-KRAS inhibitor and/or anti-PD1 treatment combinations 9 samples shares anti-pd1, treatment
- GSE142634 Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture 29 samples shares evaluation, treatment
- GSE314869 Potential of an in vitro mouse testicular organ culture system as a platform for mechanism-based evaluation of testicular toxicity 17 samples shares evaluation, potential
- GSE193121 Evaluation of potential impact of anti-LIF therapy on the tumor microenvironment in the immune-component mice by scRNA-seq analysis. 4 samples shares evaluation, potential
- GSE248155 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma 31 samples shares anti-pd1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.